Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors.
Janjigian YY, Lee W, Kris MG, Miller VA, Krug LM, Azzoli CG, Senturk E, Calcutt MW, Rizvi NA. Janjigian YY, et al. Cancer Chemother Pharmacol. 2010 Apr;65(5):833-8. doi: 10.1007/s00280-009-1088-4. Epub 2009 Aug 12. Cancer Chemother Pharmacol. 2010. PMID: 19672598 Free PMC article. Clinical Trial.
MET expression and amplification in patients with localized gastric cancer.
Janjigian YY, Tang LH, Coit DG, Kelsen DP, Francone TD, Weiser MR, Jhanwar SC, Shah MA. Janjigian YY, et al. Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):1021-7. doi: 10.1158/1055-9965.EPI-10-1080. Epub 2011 Mar 10. Cancer Epidemiol Biomarkers Prev. 2011. PMID: 21393565 Free PMC article.
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ, Melnick MA, Riely GJ, Kris MG, Miller VA, Ladanyi M, Politi K, Pao W. Takezawa K, et al. Among authors: janjigian yy. Cancer Discov. 2012 Oct;2(10):922-33. doi: 10.1158/2159-8290.CD-12-0108. Epub 2012 Sep 5. Cancer Discov. 2012. PMID: 22956644 Free PMC article.
Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
D'Angelo SP, Janjigian YY, Ahye N, Riely GJ, Chaft JE, Sima CS, Shen R, Zheng J, Dycoco J, Kris MG, Zakowski MF, Ladanyi M, Rusch V, Azzoli CG. D'Angelo SP, et al. Among authors: janjigian yy. J Thorac Oncol. 2012 Dec;7(12):1815-1822. doi: 10.1097/JTO.0b013e31826bb7b2. J Thorac Oncol. 2012. PMID: 23154553 Free article.
167 results